

Product Center
The launch ceremony of the four valent influenza virus subunit vaccine Huierkangxin was successfully held!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-26
- Views:
(Summary description)On September 25th, the inaugural ceremony of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
The launch ceremony of the four valent influenza virus subunit vaccine Huierkangxin was successfully held!
(Summary description)On September 25th, the inaugural ceremony of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-26 10:00
- Views:
On September 25th, the inaugural ceremony of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine Huierkangxin was successfully held.
At the inaugural ceremony, Mr. An Youcai, Chairman and General Manager, reviewed the eight years of hard work, affirmed his achievements, and looked forward to the future. He proposed that only through innovation can we go far, and we must firmly adhere to the five-year strategic goals, forge ahead, and jointly build a defense line for human health!
The official launch of Huier Kangxin will bring society more advanced, safer, and effective choices for influenza vaccination, reduce hesitation in vaccination, further improve the influenza vaccination rate, and assist in China's influenza prevention and control!
Relevant information
-
Ab&B Bio and Yither Bio have both obtained qualification certification!
Recently, Ab&B Bio-Tech Co.,Ltd(Ab&B Bio) and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) have been recognized as Jiangsu Province's specialized and innovative small and medium-sized enterprises and national high-tech enterprises, respectively. - The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held 12-25
- Influenza virus subunit vaccine (adjuvant) IND application approved 10-30
- The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
Have a project?Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us